

Gene modified mesenchymal stromal cells for stroke: Mechanism and path to the clinic

Casey Case

SanBio, USA

SB623 is an adult stem cell product derived from mesenchymal stromal cells (MSCs) by transient transfection with Notch-1. It has proven effective in a variety of neurodegenerative disease models. SB623 is not a cell replacement therapy. It works by mechanisms including trophic support, production of beneficial extracellular matrix and immuno-modulation. A clinical trial has been initiated in patients with stable stroke deficits. This talk will focus on the mechanism of action and the translation of this product from bench to clinic.

Biography

Casey Case is an Executive Vice President; Research at SanBio Inc. SanBio is developing cell therapies for the regeneration of the central nervous system. He joined SanBio in 2006. Previously, Dr. Case was the Vice President, Research at Sangamo Biosciences. He played a leading role in the development of Sangamo's zinc finger technology. He held Director Positions at Tularik and OSI Pharmaceuticals. He has a Ph.D. in Biochemistry from University of California, Davis, did postdoctoral studies at UCLA, and is an inventor on 29 issued US patents.

Casey.Case@san-bio.com